My Profile   |   Print Page   |   Contact Us   |   Sign In   |   Register
ASAP Blog
Blog Home All Blogs
Welcome to ASAP Blog, the best place to stay current regarding upcoming events, member companies, the latest trends, and leaders in the industry. Blogs are posted at least once a week; members may subscribe to receive notifications when new blogs are posted by clicking the "Subscribe" link above.

 

Search all posts for:   

 

Top tags: alliance management  alliances  collaboration  partnering  alliance  partner  partners  partnerships  alliance managers  ecosystem  alliance manager  The Rhythm of Business  partnership  Jan Twombly  Vantage Partners  biopharma  Eli Lilly and Company  governance  strategy  Strategic Alliance Magazine  IBM  collaborations  IoT  strategic alliances  ASAP BioPharma Conference  cloud  innovation  Christine Carberry  Cisco  healthcare 

New Offerings at ASAP BioPharma Conference Address Wide-ranging Impacts on the Healthcare and Life Sciences Industries

Posted By Cynthia B. Hanson, Saturday, August 27, 2016

As futuristic technologies become realities, professionals in the life sciences and healthcare industries are consulting their maps and charts to determine how their companies should navigate the new waters. Attendees at ASAP’s next BioPharma Conference will have an opportunity to collectively view the vast possibilities at “New Faces, Unexpected Places in Partnering: The Foresight to Lead, the Foundation to Succeed,” Sept. 7-9 at the Revere Hotel in Boston, Mass., USA. This year’s conference will address wide-ranging impacts on the industry, including the changing political scene, multi-partnering, the Internet of Things, and assistive technologies. 

 

After a rich offering of workshops on Sept. 7, the conference will kick off with a timely address from keynote speaker Dr. Sam Nussbaum, strategic consultant, EGB Advisors, Inc., who will present a talk on “Healing the U.S. Health Care System: Collaboration is Essential” (for more information about Nussbaum, see the link in this E-news), followed by a networking opportunity. The following two days include a plenary and about 26 forward-thinking, thought-provoking sessions from which to choose.

 

"The ASAP Biopharma Conference is a must-attend for alliance professionals of all experience levels,” says Jan Twombly, CSAP, former ASAP chairman of programming, and president of The Rhythm of Business. “It traditionally offers equal parts of looking outward to how the industry is changing and the implications for managing the risk and optimizing the value of alliances and other collaborations, as well as looking inward to develop the mindset, skillset, and toolset of a modern alliance capability.”

 

Well-known and respected industry luminaries are unveiling some never-before-presented information and perspectives. Take, for example, these insightful offerings:

  •  “Applying the Latest Alliance Management Research to Your Partnering Practice,” presented by Stuart Kliman, CA-AM, partner, alliance practice leader at Vantage Partners, and Shawn Wilson, DBA, vice president and general manager at Beaulieu Group: Two new groundbreaking research studies provide critical data on current trends, challenges, and opportunities in the alliance management profession.
  • “A New Model for Western and Chinese Pharmaceutical Partnering,” presented by Brent Harvey, CA-AM, director of Alliances, Eli Lilly and Company: "How To" insights on collaboration drawn from a longstanding, advanced partnership model between Eli Lilly and Company and WuXi AppTech, which provides, among other things, examples of how to leverage the regulatory environment in China to bring new drugs to market faster.
  • “New Partnerships between High Tech and BioPharma and the Alliance Management Practices to Support Them,” presented by Russ Buchanan, CSAP head of corporate alliances at Xerox Corporation, Joseph Schramm, VP strategic alliances at BeyondTrust, and David Thompson, CA-AM chief alliance officer at Eli Lilly and Company: Key insights provided by two highly accomplished technology company alliance executives that are sure to generate discussion about how biopharma alliance professionals can overcome potential challenges when partnering with tech companies.

 Preparing for rapid change is a central theme throughout the conference, and some of the workshops are offering essential “updates” for the alliance management toolbox. “With many more partners for many more purposes, new partnering models and differences to leverage, no alliance manager can rest on his or her laurels,” points out Twombly. “Unique among biopharma alliance management conferences, the ASAP Biopharma Conference leans in on where the profession is going, not where it has been."

 

Several workshops being offered emphasize the need to stay abreast of pressing industry changes, such as “Next Generation Alliance Management, Lean and Agile” facilitated by Lynda McDermott, CA-AM, president of EquiPro International, and Annick De Swaef, CSAP, managing partner of Consensa Consulting. Their workshop addresses digitalization’s influence on biopharma and cross-industry partnering, and it centers around basic questions that everyone in the industry is asking: “Are my team's current alliance best practices future proof? Should my alliance team acquire new skills?” De Swaef recommends combining ASAP’s newly launched in-company team training with the CA-AM Certification Exam Prep to strengthen company capabilities, expand into new areas of value creation, and introduce new best practices.

 

Twombly and Rhythm of Business Principal, Jeff Shuman, CSAP, are offering their own forward-thinking, 90-minute, hands-on workshop on design thinking for complex problems, such as for multi-partnering, non-asset-base alliances, and partnering with “sectors who run on much faster clock speeds than is typically seen in biopharma.” The data-driven, user experience-centered innovation and problem-solving methodology has been adapted for alliances and partnering practices.

 ASAP also plans to unveil a new custom-designed session: The ASAP Aquarium, facilitated by Twombly. Similar to a “fishbowl” communications activity, where the line is intentionally blurred between listeners and participants, ASAP’s version will start off with a deep discussion between industry thought leaders and senior-level partnering executives as the audience gazes into the aquarium. Listeners will then be able to “tap in,” join the discussion with a hot idea or new perspective, and replace the initial participants. The session provides for a fun way to actively engage and contribute to the collective wisdom of the group while exploring the questions that matter most as alliance professionals “engage with new faces and in unexpected places.”

Tags:  Alliance Professionals  Annick De Swaef  ASAP BioPharma Conference  BeyondTrust  Brent Harvey  collaboration  David Thompson  Dr. Sam Nussbaum  Eli Lilly and Company  EquiPro International  Jan Twombly  Jeff Shuman  Joseph Schramm  Lynda McDermott  Russ Buchanan  The Rhythm of Business  WuXi AppTech  Xerox 

Share |
PermalinkComments (0)
 

Maximizing the Alliance Management and C-Suite Relationship Through the Eyes of Biopharma Conference Plenary Speaker Stéphane Thiroloix

Posted By Cynthia B. Hanson, Monday, August 1, 2016
Updated: Sunday, July 31, 2016

Stéphane Thiroloix describes himself as a “reasonable generalist,” having been involved with partnering in multiple waysfrom business development, general management, marketing, and sales to R&D and legal affairs. The CEO at Mayoly Spindler, an emerging family-owned, independent French company with a focus on gastroenterology and dermocosmetics, will present a plenary talk on The View from the C-Suite: Partnering and Alliances Today and Tomorrow,” Thursday morning, Sept. 8, during the 2016 ASAP BioPharma Conference. This year’s conference, “New Faces, Unexpected Places in Partnering: The Foresight to Lead, the Foundation to Succeed,” will be held Sept. 7-9 at the Revere Hotel in Boston. Mayoly Spindler’s revenue originates half in France and half abroad through activities in over 50 countries, mostly via local partnerships. The company’s portfolio strategy is based almost exclusively on partnering. Thiroloix provided this preview of his topic on how alliance management functions can best be viewed and leveraged by company senior leadership.

What are some of the challenges when coordinating the alliance management and C-Suite relationships?
The first challenge is simply understanding the role of alliance management. When you have skilled and proactive alliance managers, it does not take long for the C-Suite to appreciate their work and turn to them constantly. Another challenge is keeping the alliance manager in play at all times, even when a partner is tempted to take a more direct CEO-to-CEO route. While that’s a perfectly legitimate move, it’s then the CEO's responsibility to keep the alliance manager in play, even if it’s transiently unofficial. One interesting challenge is accepting contradictions from the alliance manager as they stand for partner interests. It’s easy to state and posture that the alliance manager is our partner's ambassador in our ExCom [executive committee], but when they make the partner's case in a difficult decision, we may feel a little strain as we remind ourselves that we hired them to do so and should pay attention.

Among your proposed discussion topics is the importance of establishing an alliance management function and its value to the senior executive team. Why has this become increasingly important in the new ecosystem?
The pharma model has become tremendously fragmented. When I started my professional life, large pharma companies were the norm, and they were fully integrated—from fundamental research to sales. Partnerships were the exception rather than the norm, and we relied mostly on our internal dynamics to succeed. Today, not only is there a constellation of small, ultra-specialized players, but even the large pharma players outsource vast quantities of strategic activities, including entire components of their R&D, most of their manufacturing, and frequently their commercial activity. As a result, the way we work today is intrinsically alliance-based. Additionally, it’s not about whether you're big or small. If you are a big, dominant player, there is high risk that you will be overpowering in your partnerships. Partners used to accept this because partnering with big pharma was the grail. That’s no longer the case, so big players need alliance management to maintain a healthy balance in their dealings with smaller players who have a variety of other doors to knock on. If you are a small player, you must be agile, humble, and alliance-focused in order to quickly build a strong partnering track record.

Describe some effective strategies partnering professionals can use to support the C-Suite?
A straight answer may be a little simplistic. The company (and its C-Suite), its partners and the alliance manager themselves, have a specific profile and style that may call for different approaches. The C-Suite requires a difficult balance between boring them with systematic activity reporting and appearing to withhold knowledge that provides an edge—which is unbearable to the C-Suite. What I've seen work well is to use the pace of partnership governance: at ExCom meetings before key alliance governance moments, provide relevant updates and gather C-Suite insight. That way you will not be covering all topics all the time. Make sure you share partner milestones to provide the C-Suite with opportunities to react in a constructive manner. If a partner cleared an FDA hurdle or raised capital, some C-Suite members may want to send a congratulatory note—but if you don’t point it out, they might miss the occasion. The best way to work the C-Suite is unquestionably to work more with their teams than with them. Similarly, make sure the C-Suite's personal assistants know where to find alliance reports, and develop flexibility and opportunities for them to connect with bosses whenever they need to deal with the alliance. Be ready to explain the same things again and again. And never, ever surprise them.

Tags:  alliance management  alliances  C-Suite  ecosystem  FDA  governance  Mayoly Spindler  partners  partnership  Stéphane Thiroloix 

Share |
PermalinkComments (0)
 

Unaligned Is the New Black in Partners

Posted By Larry Walsh, CEO and Chief Analyst of The 2112 Group., Monday, August 1, 2016
Updated: Sunday, July 31, 2016

More solution providers and resellers are forgoing vendor loyalty in favor of independence based on their own technical prowess and business savvy. What they lack in loyalty, they make up for in influence.

Defined by autonomy, these are the partners that align with vendors, but keep loyalty out of the mix. It’s not that they don’t value loyalty, or that they deem vendors untrustworthy. It’s just that they feel more comfortable flying solo. On the flip side, some of these partners won’t align themselves with any vendor at all.

Aligned partners without loyalty are putting their capabilities and services first. They see their value and viability in their intrinsic technology skills, domain expertise, and problem-solving capabilities. They’ve grown tired of the sales treadmill in which they earn pennies on the dollar for shilling products, and still have to perform services to make money. Maintaining vendor relationships comes with a partnership tax – the need to comply with expensive and distracting training, certification, and performance requirements. Instead, they’re letting the volume resellers – CDW, SHI, and Insight, for example – sell the product, and then they clean up by delivering the services.

Another facet of today’s vendor community that’s fueling independence in the technology channel is turmoil. As vendors go through difficult transitions – evolving business models, disruptive competition, and so forth – that chaos trickles down to the partner level. Some would rather sit and observe than get tossed into the storm.

Read the full 2112 Group article, Unaligned Is the New Black in Partners

ASAP Corporate Member, EPPP and guest blogger, Larry Walsh is CEO and chief analyst of The 2112 Group.

Tags:  Larry Walsh  partners  solution providers  technology channel  The 2112 Group  vendors 

Share |
PermalinkComments (0)
 

What’s Brewing in the 2016 Biopharma Conference Beaker? | Part 2

Posted By Cynthia B. Hanson, Wednesday, July 20, 2016
Updated: Tuesday, July 19, 2016

In a recent interview, ASAP CEO Mike Leonetti, CSAP, provided a sampling of what’s to come at the 2016 ASAP BioPharma Conference. He offered insights into the changing landscape for partnerships and how alliance managers and others need to adapt, as well as a preview of speakers and cutting edge sessions and workshops. 

What about ASAP? What’s brewing in the beaker and will be shared at the conference?

We will be unveiling, and introducing the author of, ASAP’s new study “The Economics of Alliances, Social Capital, and Alliance Performance,” which is scheduled for release after the conference as ASAP’s 6th State of Alliances study. You can read a preview of the study and view some of the research data in the upcoming Summer Strategic Alliance Magazine. Dr. Shawn Wilson, the author, has worked with ASAP to provide financial and economic return on investment (ROI) analytics that are a direct outcome of alliance/partnership management excellence.

What are some of the cutting edge, not-to-be-missed sessions you recommend?

While every session is going to be fantastic, the session that discusses digital or tech partnering capabilities, “New Partnerships between High Tech and BioPharma and the Alliance Management Practices to Support Them,” led by Russ Buchanan, CSAP, head of corporate alliances, Xerox Corporation, and “New Partnerships Between High Tech and BioPharma and the Alliance Management Practices to Support Them,” facilitated by Donna Peek, CSAP, director, partner enablement & operations at SAS Institute, will be timely. The unveiling of ASAP’s research and “Applying the Latest Alliance Management Research to Your Partnering Practice,” by Shawn Wilson, in conjunction with Stuart Kliman, CA-AM, who is presenting Vantage Partners’ research findings, should not be missed.  I think the sessions on “Strategic Perspectives on a Partnership's First 100 Days” offer a new twist on partnering with new players. Another session on partnering in China addresses the crucial need to understand and learn about that country, “A New Model for Western and Chinese Pharmaceutical Partnering,” by Brent Harvey, CA-AM, director, alliance management at Eli Lilly and Company.

Every year ASAP provides workshops for the alliance management toolbox. What’s new in the box this year?

There are several fantastic “Tools and Techniques” pre-conference workshops, the CA-AM and CSAP prep workshops, the Eli Lilly and Company “Alliance Management, Tools and Techniques, “ which never fails to draw rave reviews, as well as one from Candido Arreche, CA-AM, global director of portfolio & partner management, six sigma black belt at Xerox Worldwide Alliances, on “How to Resolve Conflict in Your Alliance.” New to ASAP is the workshop “Next Generation Alliance Management, Lean and Agile,” facilitated by Lynda McDermott, CA-AM, president of Equipro International, and Annick De Swaef, CSAP, president of Consensa, which will preview ASAP’s new corporate alliance management and certification program designed to offer a customized workshop for a company wishing to quickly add to its partnership capability and value creation.

To view the program and download brochure information, go to www. asapweb.org/biopharma.

Tags:  Alliance Management  Annick DeSwaef  Brent Harvey  Candido Arreche  certification  Consensa  digital  Donna Peek  Dr. Shawn Wilson  Eli Lilly and Company  Equipro International  Lynda McDermott  partnership  Russ Buchanan  SAS  Stuart Kliman  Vantage Partners  Xerox Worldwide Alliances 

Share |
PermalinkComments (0)
 

What’s Brewing in the 2016 Biopharma Conference Beaker? | Part 1

Posted By Cynthia B. Hanson, Tuesday, July 19, 2016

In a recent interview, ASAP CEO Mike Leonetti, CSAP, provided a sampling of what’s to come at the 2016 ASAP BioPharma Conference. He offered insights into the changing landscape for partnerships and how alliance managers and others need to adapt, as well as a preview of speakers and cutting edge sessions and workshops.  

Why is this a must-attend conference for alliance managers, CEOs, and others working in the biopharma, healthcare, and life sciences industries? 

Partnership management is changing. If they are performing their jobs the same way they were two years ago, they likely are leaving money on the table or missing great new opportunities. This year’s conference offers programming to learn how to partner in new environments, which includes tech, academic, and healthcare system partnerships. An ongoing message of the conference is to understand that the ecosystem is getting larger, and their enterprise now represents their company, partners, and the entire healthcare system. As alliance managers, we can no longer be comfortable defining our box as an asset partnership and staying there. We will limit our creation of value in our companies unless we harvest the enterprise. 

What’s new at this year’s conference? 

We are going to talk a lot about the changes in partnerships across the industry. We are not only going to talk about biopharma and healthcare, we are going to hear from people on the tech side of ASAP regarding what’s important and best practices when partnering with tech. It will provide key opportunities to learn about tech companies and how they partner. If biopharma and healthcare are going to partner with tech, each of these industries needs to have a clear understanding of the others’ expectations. 

What timely message is Dr. Samuel Nussbaum, strategic consultant at EGB Advisors, Inc., likely to provide during his keynote address? 

The keynote, “Healing the U.S. Health Care System: Collaboration is Essential,” which is scheduled for the afternoon of Wed., Sept. 7, will tie directly into our theme. Sam is going to talk about his background and expertise with the impact of public policy on healthcare systems and healthcare reform. He will talk a lot about how important collaboration is to finding a solution to our system crisis; my guess is he may try to give examples of how manufacturers, payers, policy experts, academics, and anybody else in the healthcare system can collaborate and partner to overcome major obstacles regarding healthcare reform. 

Who will give the plenary address? 

Our plenary will be given by Stéphane Thiroloix, CEO of Mayoly Spindler, on the morning of Thurs., Sept. 8. Mayoly Spindler is an emerging family-owned, independent French company, originally founded by a husband-and-wife team working to provide gastroenterology and dermatology healthcare solutions. Stéphane joined as managing director in 2014, and he has lots of leadership experience from working in multiple biopharma executive roles before joining Mayoly Spindler. He is an advocate who understands what it takes to be successful in a partnership and basically created the partnership management function in his last two roles.  He will share what a CEO’s expectations are for alliance management success. 

To view the program and download brochure information, go to www. asapweb.org/biopharma.

Tags:  alliance management  biopharma  collaborate  Dr. Samuel Nussbaum  ecosystem  healthcare  healthcare reform  Mayoly Spindler  partner  partnership  Partnership management  Partnerships  public policy  Stéphane Thiroloix  tech 

Share |
PermalinkComments (0)
 
Page 47 of 93
 |<   <<   <  42  |  43  |  44  |  45  |  46  |  47  |  48  |  49  |  50  |  51  |  52  >   >>   >| 
For more information email us at info@strategic-alliances.org or call +1-781-562-1630